Oberland pours up to $400M into MeiraGTx eye gene therapies

An article from Oberland pours up to $400M into MeiraGTx eye gene therapies The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J. Published July 7, 2026 Delilah Alvarado Reporter Share Copy link Email LinkedIn X/Twitter Facebook Print License Add us on Google MeiraGTx is gaining up to $400 million in funding from investment firm Oberland Capital Management to help support the potential launches of gene therapies it’s been developing for inherited eye conditions. Through a deal announced Tuesday, Oberland will provide MeiraGTx with as much as $375 million in financing and up to $25 million in the form of an equity investment. In return, Oberland will receive single-digit royalties on the three MeiraGTx candidates involved in the agreement, all of which are being developed for different eye diseases. MeiraGTx could potentially bring three treatments to market in the next year or two. One, for an ultra-rare, blinding condition called Leber congenital amaurosis-4, was licensed to Eli Lilly last November. MeiraGTx owns rights to the other two: bota-vec, for X-linked retinitis pigmentosa, and AAV2-hAQP1 for radiation-induced xerostomia. In a statement, MeiraGTx CEO and president Alexandria Forbes said the new investment demonstrates “exceptional confidence” in the data supporting those programs as well as the sales potential of bota-vec and AAV2-hAQP1 specifically. MeiraGTx expects to report data from a pivotal study of AAV2-hAQP1 in the second quarter of next year, with a potential approval following in 2027 and a U.S. launch as early as 2028. In April, the company reported positive three-year data from an early trial of the therapy, which could be eligible for a “priority review” from the Food and Drug Administration. Less clear is the future of bota-vec. Johnson & Johnson once worked with MeiraGTx on the therapy, but the treatment missed its main objective in a late-stage trial last year and the big drugmaker returned ownership rights in April. MeiraGTx, though, has been optimistic about a clarance given other benefits observed in testing. “MeiraGTx is in the rare position of having three potentially approvable therapies within the next 12 to 24 months, two of which have significant commercial potential” and would be “first to market in areas of complete unmet need,” said Oberland partner Michael Bloom, in the statement. Add us on Google Share Copy link Email LinkedIn X/Twitter Facebook Print License Filed Under: Biotech, Deals